Keyword: U.S. Department of Justice
After months of settlement talks—and as it works with HHS against COVID-19—Teva broke off communications with federal prosecutors, reports say.
With only the Federal Trade Commission left to clear in their $63 billion merger, AbbVie and Allergan may face a delay due to the novel coronavirus.
Only weeks after a former exec in its Sandoz unit pleaded guilty to federal charges, Novartis will pony up $195 million to escape price-fixing claims.
With a seven-figure opioid settlement in the works and its generics unit facing bankruptcy, Mallinckrodt will lean on Acthar Gel for future growth.
Mallinckrodt has taken a hard look at bankruptcy in recent months. On Tuesday, the company pulled the trigger as part of a $1.6 billion opioid deal.
A third generics executive has been charged in a long-running price-fixing probe that has also yielded a settlement with two drugmakers.
With federal prosecutors laying waste to Insys' executive team, one big domino was still left to fall: Founder and former CEO John Kapoor.
WIth its megamerger with AbbVie nearing a close, Allergan will pay $300 million to settle claims against its Warner Chilcott and Watson businesses.
A federal judge said prosecutors failed to present enough evidence to charge Insys founder John Kapoor on conspiracy in the drugmaker's Subsys sales.
As Insys reaches the last days of its bankruptcy liquidation, it's offering to settle its opioid overhang at pennies on the dollar for plaintiffs.